KPV Peptide: Legal Status and What the Research Shows

Legal status of KPV

Waiting on FDA after a favorable vote

KPV won a favorable but nonbinding advisory committee vote in July 2026, and FDA has not acted on it ^[3]. It still cannot be legally compounded or sold as a drug ^[1].

FDA status

FDA removed it from Category 2 in April 2026 because the nominators withdrew their nominations ^[7]. That removal did not make it legal to compound ^[9]. FDA now lists it as "nominated but withdrawn," which is outside every category ^[8]. It is not in Category 1 and is not on the 503A bulks list, so a 503A pharmacy may not lawfully compound it today ^[1]. FDA found no clinical trials or human drug level data for KPV, only lab and animal data ^[4].

Advisory committee

On July 23, 2026, the committee voted 8 yes, 6 no and 1 abstain to recommend adding KPV to the 503A bulks list ^{[2] [10]}. The committee reviewed it for wound healing and inflammatory conditions ^[15]. FDA staff had recommended against listing it ^[4]. FDA has not posted its own vote count on the meeting page ^[15]. Advisory committee votes are not binding. Nothing changes until FDA acts ^[5].

FDA-approved products

None. We found no FDA-approved drug that contains KPV.

Sports (WADA)

KPV is not named on the 2026 list ^[13]. The list's S0 class covers substances with no approval by any government health authority for human use ^[13]. Whether that class covers KPV is a judgment call, so athletes should ask their anti-doping agency before use.

What happens next

To add it to the 503A bulks list, FDA must go through notice-and-comment rulemaking, starting with a proposed rule. FDA could also place it in Category 1 or announce enforcement discretion in the meantime ^[5]. As of Oct 16, 2026, FDA had not started rulemaking or moved any of these peptides to Category 1 ^[3]. HHS has sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House budget office for review. Holland & Knight dates that submission Oct 14, 2026 ^[3], while the AP reported it appeared on a government website on Oct 15 ^[11]. The policy has not been issued and its text is not public ^[3]; reporting on Oct 21, 2026 still described it as under review ^[17]. Reports say it would cover some popular peptides, but we could not confirm whether KPV is one of them ^[11]. One law firm says there is no reliable timetable for final action ^[5]. A drug safety group petitioned FDA on Oct 16, 2026 not to allow it ^[12].

Checked against FDA sources on Oct 24, 2026. We update this box when FDA acts. Report a change: [email protected].

KPV in plain words

FDA's briefing calls KPV "a tripeptide composed of the amino acids lysine (K), proline (P), and valine (V)," a fragment of alpha-MSH, a hormone made in the pituitary gland ^[4]. The nomination proposed a 0.1% cream or gel for wound healing and inflammatory conditions such as psoriasis and eczema ^[4]. Online, sellers market it in other forms and for other uses, including the gut. None of those products has been reviewed by FDA as a drug ^[1].

Can a doctor prescribe KPV?

A doctor can write anything on a prescription, but a pharmacy may not lawfully fill it with KPV. Federal law limits 503A pharmacies to bulk ingredients that have a USP or NF monograph, are part of an approved drug, or are on FDA's bulks list ^[6]. KPV has none of these, and it is not in Category 1, the only interim group FDA leaves alone ^[1].

KPV was one of 12 peptides FDA took out of its Category 2 safety-risk group in April 2026 because the nominators withdrew ^[7]. That step moved it to a "nominated but withdrawn" list, which allows nothing ^{[8] [9]}. Then came the July vote, which law firm reports put at 8-6-1 ^{[2] [10]}. FDA staff had recommended against it ^[4].

What would change it

FDA would have to issue a proposed rule, place KPV in Category 1, or announce that it will not enforce against pharmacies compounding it ^[5]. As of Oct 16, 2026 it had done none of these ^[3]. An interim access policy reached the White House budget office in mid-October; reports say it covers some popular peptides, but we could not confirm KPV is one of them ^{[11] [3]}. A drug safety group filed a citizen petition on Oct 16, 2026 asking FDA to hold off on KPV and six other peptides ^[12].

The evidence: lab dishes and animals

FDA summarized the record as "nonclinical pharmacological studies suggesting that KPV-related BDSs can have antiinflammatory and wound-healing properties in in-vivo and in-vitro models" ^[4]. Put simply: some anti-inflammatory and healing signals in cells and animals. FDA added that KPV's molecular targets "remain unknown" ^[4].

On people, the briefing is short: "FDA did not find information on products containing KPV (free base) or KPV acetate administered in humans" ^[4]. FDA wrote that it was particularly concerned about that gap ^[4].

Why a cream may not reach its target

One finding cuts both ways. In a lab test on human cadaver skin, KPV did not pass through the skin well ^[4]. FDA noted that this could limit whole-body side effects, and also limit whether a cream works at all ^[4]. For a product nominated as a skin cream, that is a basic open question.

Known and unknown risks

FDA wrote that "potential safety risks associated with the use in humans are unknown" and that data on immune reactions and clumping (aggregation) are insufficient ^[4]. FDA's safety page adds that it has not identified any human exposure data on products containing KPV ^[8]. Without a human study, no seller can tell you the side effect rate.

KPV and anti-doping rules

KPV is not named on the 2026 WADA Prohibited List ^[13]. The list's S0 class covers any substance with no approval from any government health authority for human use ^[13]. KPV has no such approval that we found, so it may fall under S0, but that is a judgment for the anti-doping agency. Athletes should ask theirs before using it.

Legal ways to get KPV

Products sold as "research use only" are not a legal workaround; FDA rejected that label in a 2025 warning letter ^[14]. KPV also appears in four-peptide blends; see our KLOW page. For the other peptides from the same July vote, see BPC-157; for another peptide marketed for inflammation and immunity, see LL-37 and our peptide FDA status tracker. Peptides that can be prescribed today are on the legal peptide price tracker, and FDA-approved options for gut and skin conditions are a question for your doctor. For context on how online peptide sellers operate, see research-use-only GLP-1s.

Status history

• Oct 16, 2026: The Partnership for Safe Medicines filed a citizen petition asking FDA not to allow compounding of this and six other peptides, by rule, Category 1 placement or enforcement discretion ^[12].
• Oct 14, 2026: HHS sent an interim peptide access policy to the White House budget office for review, per Holland & Knight ^[3]. The AP reported it appeared on Oct 15 ^[11]. It has not been issued ^[3].
• Jul 23, 2026: On July 23, 2026, the committee voted 8 yes, 6 no and 1 abstain to recommend adding KPV to the 503A bulks list ^{[2] [10]}.
• May 12, 2026: FDA staff briefing documents recommended against adding it to the 503A bulks list ^[4].
• Apr 22, 2026: The removal took effect around this date. FDA now lists it as nominated but withdrawn, which does not allow compounding ^{[8] [9]}.
• Apr 15, 2026: FDA gave seven days' notice that it would remove 12 peptides, including this one, from Category 2 because the nominators withdrew ^[7].
• Sep 29, 2023: FDA placed it in Category 2, citing significant safety risks ^[16].

The other peptides FDA's committee weighed in July 2026: TB-500, MOTS-c, Semax, epitalon and DSIP. For approved peptide drugs, see PT-141 and SS-31.

How this page is checked

We read FDA's categories document, the KPV briefing and FDA's advisory committee pages, and we rechecked them on Oct 24, 2026 ^{[1] [15]}. Vote counts come from law firm and trade reports because FDA has not posted minutes ^[2]. We do not link to sellers. See our editorial standards.